



EAES rapid guideline: surgical management of complicated diverticulitis – with ESCP participation

Stavros A. Antoniou^{1,2} · Bright Huo³  · Monica Ortenzi⁴ · Roi Anteby^{5,6} · Yegor Tryliskyy⁷ · Francesco Maria Carrano⁸ · Georgios Seitidis⁹ · Dimitris Mavridis⁹ · Vincent T. Hoek¹⁰ · Alberto Serventi¹¹ · Willem A. Bemelman¹² · Gian Andrea Binda¹³ · Rafael Duran¹⁴ · Triantafyllos Doulias^{15,16,17} · Nauzer Forbes^{18,19} · Nader K. Francis²⁰ · Fabian Grass²¹ · Jesper Jensen²² · Marianne Krogsgaard²³ · Lisa H. Massey²⁴ · Luca Morelli²⁵ · Christian E. Oberkofler^{26,27} · Dorin E. Popa²⁸ · Johannes Kurt Schultz^{29,30,31} · Shahnaz Sultan³² · Jean-Jacques Tuech³³ · Hendrik Jaap Bonjer^{34,35}

Received: 23 August 2024 / Accepted: 23 November 2024 / Published online: 28 December 2024
© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2024

Abstract

Background The surgical management of complicated diverticulitis varies across Europe. EAES members prioritized this topic to be addressed by a clinical practice guideline through an online questionnaire.

Objective To develop evidence-informed clinical practice recommendations for key stakeholders involved in the treatment of complicated diverticulitis; to improve operative and perioperative outcomes, patient experience and quality of life through a systematic evidence-to-decision approach by a diverse, multidisciplinary panel.

Methods Informed by a linked individual participant data network meta-analysis of resection and primary anastomosis (PRA) versus Hartmann's resection (HR) versus laparoscopic lavage (LPL), a panel of general and colorectal surgeons, patient partners, trialists, and fellows appraised the certainty of the evidence using GRADE and CINeMA. The panel discussed the evidence using the evidence-to-decision framework during a synchronous consensus meeting. An asynchronous modified Delphi survey was used to establish consensus.

Results The panel suggests that patients with complicated diverticulitis without sepsis receive PRA over HR or LPL when there is availability of a surgeon with skills and experience in colorectal surgery. HR is suggested over PRA or LPL in the subgroups of septic, frail, as well as immunocompromised patients. These recommendations apply to patients with an indication for surgery. Surgeons and patients should first consider conditionally recommended interventions, then conditionally recommended against. Based on the evidence, the key benefit of PRA was a higher likelihood of not having a stoma at 1 year, with similar risks across comparisons. Conditional recommendations call for shared decision-making when considering management options. The full guideline with user-friendly decision aids is available in <https://app.magicapp.org/#/guideline/7490>.

Conclusion This clinical practice guideline provides evidence-informed recommendations on the management of patients with complicated diverticulitis in accordance with the highest methodological standards through a structured framework informed by an international, multidisciplinary panel of stakeholders.

Keywords Diverticulitis · Colorectal surgery · Minimally invasive surgery · Laparoscopic surgery · Guidelines

Colonic diverticulitis carries an important burden on the general population, with an estimated 23% prevalence of colonic diverticula and a mortality of 3% in patients admitted for diverticular disease [1]. The management of acute complicated diverticulitis is manifold and depends on disease and patient characteristics and available resources [2]. Many factors are considered in the decision-making process

including disease stage, extent of inflammation, the number, location, and size of collections in cross-sectional imaging, the presence of sepsis, and patient characteristics and preferences [3]. The multitude of management options reflects the diversity of the disease and patient attributes.

Observational and randomized studies with head-to-head comparisons of competing interventions, such as open and laparoscopic Hartmann's resection (HR), laparoscopic peritoneal lavage (LPL), and primary resection

Extended author information available on the last page of the article

and anastomosis (PRA), have aimed to provide insight into the benefits and harms of treatment options [3]. Available summary analyses have two primary limitations. First, outcome assessment at the study level usually cannot account for individual patient characteristics when the number of studies is small, typically fewer than 10 [4]. Furthermore, meta-regression may consider a limited number of factors for subgroup analyses, such as disease stage and the American Society of Anesthesiologists (ASA) class, if such subgroup data are available in a fair number of studies. Second, currently available evidence syntheses summarize outcomes in pairwise comparisons, which does not allow for concurrent appraisal of multiple interventions [5].

Practice guidelines on the management of acute diverticulitis provide recommendations on complicated diverticulitis informed by evidence with such limitations in summary analyses [3, 6–8]. The Guidelines Subcommittee of the European Association for Endoscopic Surgery (EAES) decided to address this gap of clinical practice recommendations informed by best available evidence. The decision was based upon quality appraisal of published guidelines and a survey of EAES members. For an outline of the process, please refer to <https://eaes.eu/conensus-guideline-projects/>. Thirty-nine percent (confidence interval, 33–45%) of EAES members prioritized a guideline on the management of complicated diverticulitis.

This rapid guideline aims to provide recommendations on the surgical management of patients with acute complicated diverticulitis of the left colon. The objective is to inform gastrointestinal, endoscopic, and general surgeons, gastroenterologists, interventional radiologists, other healthcare professionals, policymakers, and patients and to improve operative and perioperative outcomes, patient experience, and quality of life.

Methods

This project was developed by the EAES Guidelines Subcommittee with participation of the European Society of Coloproctology (ESCP). The guideline follows AGREE-S, GRADE, Institute of Medicine, Guidelines International Network (GIN), and Cochrane Rapid Reviews Methods Group development and reporting standards [9–13]. An AGREE-S reporting checklist is provided in Supplementary File 1. GRADE guidance published in a series of articles in the *Journal of Clinical Epidemiology* was consulted for up-to-date information. The process of guideline development was facilitated using MAGICapp, an online authoring and publication platform.

Steering group

The steering group consisted of two general surgeons who either performed (SAA) or have vast experience in laparoscopic colorectal surgery (HJB). A member of the steering group is a GIN-certified lead guideline developer and chair with vast experience in evidence outreach, synthesis, assessment, and guideline development (SAA; INGUIDE certification number: 2022-L3-V1-00014) [14]. Both steering group members declared no direct nor indirect conflicts [15]. Two trainee guideline methodologists supported the development of this guideline (BH, FMC). An experienced systematic reviewer coordinated the systematic review, data collection and risk of bias assessment, performed by two systematic reviewers, as detailed in the accompanying systematic review [16].

Guideline panel

The guideline panel consisted of 2 general and 4 colorectal surgeons whose colorectal surgery practice consists primarily of minimally invasive surgery, including two members from ESCP and 2 patient partners. One patient partner was a stoma care nurse with a research background, who has also participated in other guideline development projects. Another patient partner has lived experience of complicated diverticulitis. He experienced a first episode of diverticulitis with abscess that was initially treated conservatively. Because of an enlargement of the abscess, he was offered laparoscopic lavage or laparoscopic HR. He opted for the latter and had an uneventful postoperative course. During the process of guideline development, he was in the waiting list for Hartmann's reversal, which he received after the consensus meeting and before the Delphi survey. Both participated as panel members with equal participation and voting rights. The authors of randomized trials addressing the subject of this guideline participated as external advisors with no voting rights in the evidence-to-decision framework as per Guidelines International Network principles [17]. Facilitators of individual patient data collection participated as fellows with no voting rights or active participation in the evidence-to-decision framework.

Panel members watched a short video tutorial outlining the guideline development methodology. The composition of panel members aimed to be representative of different parts of Europe and different age groups. All panel members disclosed no direct nor indirect conflicts related to the topic of this guideline [15]. A member of the GRADE Working Group participated as an external auditor (SS).

The composition of the guideline development group and each member's role are available in the online appendix [15]. An external advisor (WB), a patient partner (JJ), a systematic reviewer (RA), a fellow (VH), and a trainee methodologist (FMC) could not participate in the consensus meeting, neither on-site, nor online. All other members of the guideline development group participated in the consensus meeting on site.

Health question

This guideline addresses the following healthcare question: Should Hartmann's resection (HR), primary resection and anastomosis (PRA), or laparoscopic peritoneal lavage (LPL) be used in the surgical management of acute complicated diverticulitis?

Subgroup questions aimed to address the use of these interventions in immunocompromised patients, frail patients, patients with sepsis, and patients with Hinchey class Ib, II, III, and IV. A subgroup question aimed to address the use of laparoscopy for the interventions HR and PRA.

This guideline refers to adult patients with acute complicated diverticulitis without obstruction, who are deemed fit for open or laparoscopic surgery, as specified in the recommendations. It refers to complicated diverticulitis (phlegmon, abscess, purulent or feculent peritonitis) without obstruction.

Target users

This work is intended to assist gastrointestinal, endoscopic, and general surgeons, gastroenterologists, interventional radiologists, other healthcare professionals, policymakers, and patients in the decision on the management of complicated diverticulitis. Patients may find the patient-specific version more useful, available as Supplementary File 2. This was developed via the paid version of ChatGPT-4.0 on June 16th, 2024 by uploading a copy of a previous guideline and accompanying patient-specific version, and asking ChatGPT to create a patient version of this guideline manuscript.

Definitions

This document uses the original Hinchey classification [18]:

- Hinchey I: localized abscess (para-colic)
- Hinchey II: pelvic abscess
- Hinchey III: purulent peritonitis
- Hinchey IV: feculent peritonitis

Primarily under consideration of the surgeon and patient perspective, this guideline uses a pragmatic intention-to-treat concept. Disease classification according to Hinchey is based upon intraoperative findings.

Protocol

A protocol was developed a priori by the steering group [15]. The protocol draft was made publicly available through the EAES website and EAES members were invited through email to comment on the content. The guideline question and outcomes of interest were refined in collaboration with the panel members and the external advisors. Amendments to the protocol with justifications are provided below.

Outcome selection and determination of utility values

The steering group drafted a list of potential outcomes. Panel members independently assessed the list of draft potential outcomes and could also propose additional outcomes for review. Panel members rated the importance of the full draft list of outcomes on a scale of 1 (limited importance) to 9 (critically important) using the GRADE scale to prioritize outcomes to be evaluated for key questions in our guideline [19]. We identified outcomes scored as "important" (score 4–6) and "critical" (score 7–9) for inclusion using the median score for each outcome, as no substantial variation was obtained among panel evaluations. The selection of additional outcomes was guided by placing emphasis on patient-important outcomes while adhering to Cochrane guidance in focusing on the most relevant outcomes for patients, clinicians, and policymakers [13].

Panel members also provided their judgements on the utility of each outcome. Utility represents an individual's health experience associated with a given outcome, with 0 being the worst possible health state/death, and 1 the best possible health state.

We presented questions in the following format: "What do you consider is the utility value of major postoperative complications (Clavien–Dindo $\geq 3b$; e.g., reoperation, abdominal abscess requiring drainage)? Utility represents the strength for an individual's preference for a given outcome. Zero reflects states of health equivalent to death/worst imaginable health, and 1 reflects perfect health/best imaginable health." We selected the median utility value for each outcome unless there was significant variation in responses, in which case consensus was achieved in the in-person consensus meeting among panel members and external advisors.

Utility values were converted to absolute risk difference thresholds according to the equation Absolute Risk

Difference = [coefficient/(1—Utility)] * 1000. We used research-informed anchors as coefficients indicating trivial-to-small effect threshold (0.0135), small-to-moderate effect threshold (0.0321), and moderate-to-large effect threshold (0.0625). We obtained absolute risk thresholds for trivial/small, small/moderate, and moderate/large effects. Additionally, utility values were converted to coefficients according to the equation: Coefficient = Absolute Risk Difference * (1—Utility). We aggregated these values (positive and negative). The judgements on the effect sizes of each outcome informed discussions on the evidence-to-decision framework by comparing absolute risk differences to empirically derived absolute risk thresholds, and the net benefit or harm/burden using the aggregate coefficient compared to coefficient thresholds [20]. The outcomes were considered within a fully contextualized evidence-to-decision process [21].

We considered the importance of outcomes as follows:

- In-hospital or 30-day mortality: 8 – critical
- Major postoperative complications (30 days or in-hospital, Clavien–Dindo ≥ 3 b; includes complications of any follow-up procedures): 7 – critical
- Having a stoma at 1 year: 6 – important
- Quality of life at 2 years: 6 – important
- Mortality at 1 year: 8 – critical
- Re-intervention at 2 years: 7 – important

In the consensus meeting, the guideline panel and the external advisors considered other interventions as important (which may not be captured by the outcome ‘reintervention at 2 years’). After deliberations and online anonymous voting, the outcome ‘reintervention at 2 years’ encompassed Hartmann’s reversal, any kind of stoma reversal, planned colonic resection after lavage, percutaneous drainage of intra-abdominal collection, any colonic resection for recurrent diverticulitis, repair of abdominal wall hernia, and adhesiolysis. The survey is listed in the online appendix [15]. This was for purposes of capturing all important outcomes in comparative effect estimates, rather than conceptual relevance of the term ‘reinterventions’ with the interventions encompassed therein.

The outcomes quality of life at 2 years, mortality at 1 year, and reintervention at 2 years were prioritized by panel members and external advisors. A detailed list of ratings, proposed, included, and excluded outcomes, with justification, is provided in the appendix [15].

We considered the following utility values:

- In-hospital or 30-day mortality: 0 (corresponding to decision thresholds of 14/32/63 per 1,000 for small/moderate/large effect)

- Major postoperative complications: 0.6 (corresponding to decision thresholds of 34/80/156 per 1,000 for small/moderate/large effect)
- Having a stoma at 1 year: 0.6 (corresponding to decision thresholds of 34/80/156 per 1,000 for small/moderate/large effect)
- Quality of life at 2 years: not applicable
- Mortality at 1 year: 0 (corresponding to decision thresholds of 14/32/63 per 1,000 for small/moderate/large effect)
- Reintervention at 2 years: 0.6 (corresponding to decision thresholds of 34/80/156 per 1,000 for small/moderate/large effect)

A detailed list of utility values voted for by panel members and external advisors is provided in the appendix [15].

Systematic review

The methodology applied in the development of the systematic review and individual participant data network meta-analysis is reported in the accompanying publication.

GRADE summary of findings

We assessed the certainty of evidence from the network meta-analysis using the GRADE approach [22]. The methodology team assessed the certainty of the evidence for five domains: risk of bias, publication bias, indirectness, inconsistency, imprecision, and publication bias.

We used the CINeMA platform to summarize the risk of bias contributed by each study to the network for each outcome, and the overall risk of within study bias was determined by the highest proportion of risk of bias contributed to the network [23].

We assessed indirectness based on differences in characteristics in populations, settings, and interventions between the source studies and those referred to in this guideline. We rated down the certainty of evidence by one or two levels if substantial unexplained incoherence was found. The methodology team used minimal important differences for each outcome, calculated by transforming a priori set utility values by the guideline panel, to make judgments regarding imprecision. We used these assessments to separately assign a certainty rating of high, moderate, low, or very low for each pairwise comparison for a given outcome, illustrated with the use of GRADE evidence profiles using MAGICapp.

Evidence-to-decision framework

The steering group provided the panel with GRADE evidence summaries and supporting material one week prior to a synchronous consensus meeting, held in-person. The meeting began with a detailed presentation of the guideline development methodology. The panel then discussed concerns surrounding the evidence summaries as well as the evidence-to-decision framework and resolved disagreements by consensus [17].

We used the evidence-to-decision framework to develop recommendations by considering the following factors [24]:

- Benefits and harms of the intervention
- Certainty of the evidence
- Values and preferences of patients and healthcare providers
- Resources required
- Acceptability of the intervention
- Feasibility of implementing the intervention
- Equity

External advisors participated in discussions but were not permitted to make judgements about the evidence-to-decision domains. Following the consensus meeting, panel members participated in an online voting on the direction and strength of the recommendations and had the opportunity to suggest modifications to existing recommendations according to the GRADE methodology [25]. We considered consensus as agreement among > 80% of panel members, if after exhaustive deliberations no unanimous consensus was achieved.

Amendments to the protocol

We included six instead of seven general/colorectal surgeons in the panel, because we invited three additional non-panel members: two fellows and an external advisor. This was done primarily for logistical reasons, because experiential evidence suggests that smaller groups are more effective, and the extended panel (guideline panel and external advisors) should comprise 10–12 members per the INGUIDE Guideline Methodologist Certification Course. The panel and external advisors provided their collective judgment on the importance and determined utility values of additional prioritized outcomes (beyond the structured online prioritization process) after deliberations during the on-site consensus meeting. The outcome ‘reintervention at 2 years’ encompassed Hartmann’s reversal, any kind of stoma reversal, planned colonic resection after lavage, percutaneous drainage of intra-abdominal collection, any colonic resection

for recurrent diverticulitis, repair of abdominal wall hernia, and adhesiolysis, based on the panel’s and external advisors’ suggestion, to capture patient-relevant outcomes.

Comparison-adjusted funnel plots and Egger’s test for assessing funnel asymmetry were not conducted due to the limited number of studies (less than 10). Additionally, subgroup analyses for frailty, Hinchey class Ib, and II were not performed. Frailty data were unavailable in the individual participant data, while Hinchey class Ib and II were only observed in a small number of patients.

Comments from EAES members

A comment referred to the use of laparoscopic surgery, which is addressed in the protocol. Another comment highlighted that in a proportion of patients, laparoscopic lavage might not be the definitive treatment due to high risk of recurrent diverticulitis and that the comparison with other interventions might not be appropriate. The panel considered that, for a significant proportion of patients who had laparoscopic lavage, resection will be proposed and performed. Analyses of mortality and perioperative morbidity in this guideline considered both the primary and any additional procedures required for recurrent diverticulitis. Further, we added the outcome ‘reinterventions’ per the EAES members’ and panel members’ suggestion. Another EAES member suggested including an interventional radiologist in the panel. The guideline development group considered this as a pragmatic limitation. To address this, panel members and external advisors invited an interventional radiologist and a gastroenterologist and they provided their comments to the content. Another member asked for specification of the follow-up of each outcome; however, this could not be specified at the protocol stage, because it should be a consensus decision among panel members and external advisors. Two members asked for addressing elderly patients; however, we consider that the concept of frailty might capture contemporary healthcare questions. Nevertheless, such information was not available in the source studies.

Results

We found 14 reports of seven randomized trials [26–39]. All studies were conducted in Europe and in European populations.

We collected full individual participant data from the LADIES trial (DIVA and LOLA; $n = 196$), the DIVERTI trial ($n = 102$), the Swiss trial ($n = 62$), the Italian trial ($n = 90$), and the SCANDIV trial ($n = 145$). We could not collect data from the DILALA trial ($n = 83$; due to no availability of the data). Collected data accounted for 88% (595 out of 678) of the total.

Subgroup analyses

We found no sufficient data on frailty, and the group decided that it may not be appropriate to use age as surrogate variable. Relevant recommendations considered indirect evidence from the network and empirical evidence from the panel members and external advisors. Similarly, no sufficient evidence was available for immunocompromised patients, patients with sepsis, and patients operated on with laparoscopic surgery.

Delphi survey

The panel reached a consensus after 2 rounds of Delphi. The consensus was unanimous for all recommendations, except recommendation number 3, which was approved with 86% (6 out of 7 panel members) agreement. The evidence tables are available in Supplementary File 3. The summary of evidence-to-decision considerations is summarized in Table 1. Evidence-Informed Recommendations are illustrated in Box 1.

Box 1: Recommendations for the Surgical Management of Diverticulitis

1. In patients with complicated diverticulitis without sepsis, we suggest sigmoid resection with primary anastomosis, with or without diverting ileostomy, over Hartmann's resection or laparoscopic peritoneal lavage, if there is availability of a surgeon with skills and experience in colorectal surgery. Conditional recommendation, low certainty of evidence:

This recommendation refers to minimally invasive and open surgery, depending on the surgeon's experience and skills.

The definition of sepsis in the above recommendation refers to the Sepsis-3 criteria [40].

2. In patients with complicated diverticulitis without sepsis, we suggest Hartmann's resection over sigmoid resection with primary anastomosis or laparoscopic peritoneal lavage, if there is no availability of a surgeon with skills and experience in colorectal surgery. Conditional recommendation, low certainty of evidence:

This recommendation refers to minimally invasive and open surgery, depending on the surgeon's experience and skills.

The definition of sepsis in the above recommendation refers to the Sepsis-3 criteria [40].

3. In patients with complicated diverticulitis with sepsis, we suggest Hartmann's resection over sigmoid resection with primary anastomosis or laparoscopic peritoneal lavage. Conditional recommendation, very low certainty of indirect evidence:

This recommendation refers to minimally invasive and open surgery, depending on the surgeon's experience and skills.

The definition of sepsis in the above recommendation refers to the Sepsis-3 criteria [40].

4. In frail patients with complicated diverticulitis, we suggest Hartmann's resection over sigmoid resection with primary anastomosis or laparoscopic peritoneal lavage. Conditional recommendation, very low certainty of indirect evidence:

This recommendation refers to minimally invasive and open surgery, depending on the surgeon's experience and skills.

5. In immunocompromised patients with complicated diverticulitis, we suggest Hartmann's resection over sigmoid resection with primary anastomosis or laparoscopic peritoneal lavage. Conditional recommendation, very low certainty of indirect evidence.

This recommendation refers to minimally invasive and open surgery, depending on the surgeon's experience and skills.

No specific recommendations apply for specific Hinchey classes, because subgroup data did not allow for plausible subgroup analyses.

Recommendation statements on specific patient subgroups (e.g., patients with sepsis) and laparoscopic surgery are based upon indirect evidence and discussion among the panel within the evidence-to-decision framework.

An alternative option in the presence of sepsis is the two-stage approach, which refers to damage-control surgery with resection of the affected bowel, lavage and abdominal vacuum therapy, stabilization of the patient and planned re-laparotomy, and potential establishment of bowel continuity [41]. This option was not considered in the present guideline.

A strong recommendation means that all or almost all properly informed stakeholders (patients, surgeons, allied healthcare professionals) would opt for the recommended course of action and only in exceptional cases, the recommendation may not be followed.

A conditional recommendation means that the majority of stakeholders (patients, surgeons, allied healthcare professionals), if properly informed, would opt for the recommended course of action. However, uncertainty in the evidence and/or variability in patient preferences and

Table 1 Summary of evidence-to-decision considerations. More details and a visual summary are available in <https://app.magicapp.org/#/guideline/7490>

Benefits and harms	<p>Research evidence</p> <p>The panel noted consistent benefits for PRA across comparisons to HR and LPL. A lower risk of stoma was observed with PRA compared to HR at 1 year, while a lower risk of mortality was demonstrated with PRA compared to LPL. No significant harms were observed with PRA relative to the other two comparators</p> <p>Additional considerations</p> <p>Key evidence on quality of life was not available. Summary effects for individual outcomes and summary judgments on net benefit/harm do not account for the certainty of the evidence, which is addressed in the next domain</p> <p>No sufficient data were available to support conclusions based upon subgroup analyses. Judgments on net benefits/harms for patients with sepsis, frailty, and immunocompromised status were based upon indirect summary evidence from the study populations, as well as the experiential evidence of the panel</p> <p>With reference to PRA, the panel suggested that net benefits and harms depend on the surgeon's experience and skills in colorectal surgery</p> <p>For patients with sepsis, frailty, and immunocompromised status, the panel considered net benefit in favor of Hartmann's procedure</p> <p>For minimally invasive or open surgery, the panel suggested that net benefits and harms depend on the surgeon's experience and skills in colorectal surgery</p> <p>Summary</p> <p>The panel suggested that there is a net benefit for PRA among patients with complicated diverticulitis in reducing mortality and yielding a lower risk of having a stoma at 1 year. The harms with PRA are considered small when performed in the hands of a surgeon with experience and skills in colorectal surgery, compared to those observed with the alternatives of HR and LPL</p>	Substantial net benefits of the recommended alternative
Certainty of the evidence	<p>Research evidence</p> <p>The certainty of the evidence was considered to be low to very low across comparisons due to limited evidence on critical outcomes. The consistency of findings in sensitivity analyses increases our confidence in the effect estimates of primary analyses. The panel considered the global certainty of the network of evidence to be low to moderate</p> <p>Summary</p> <p>The overall certainty of the evidence was considered to be low to moderate</p>	Low to moderate

Table 1 (continued)

Preferences and values	<p>Research evidence</p> <p>A scoping search of the literature (search string (“diverticulitis” OR “diverticular disease”) AND (“patient preference”[mh] OR preference[ti] OR preferences[ti])) search performed on April 10, 2024 did not identify relevant evidence on patient’s values and preferences</p> <p>Additional considerations</p> <p>The panel noted that there would be no variability in patient values and preferences for perioperative mortality. However, there would likely be substantial variation in values and preferences for major complications, due to the wide spectrum of potential major complications</p> <p>Furthermore, summary data were presented that suggest that patients assign high utility ratings to having a stoma after receiving one, whether for malignant or benign reasons.¹</p> <p>However, patients with diverticulitis often present emergently and may have inferior outcomes due to the placement of a stoma without the involvement of a stoma nurse. Many of the panel members also still felt that patients would vary in their preferences prior to receiving a stoma, and thus the panel anticipated substantial variability across the outcomes studied here</p> <p>Summary</p> <p>The panel concluded that substantial variability is expected across the outcomes studied here due to the diversity in potential major complications, as well as the emergent nature of stoma placement</p>	Substantial variability is expected or uncertain
Resources	<p>Research evidence</p> <p>Three recent articles were found providing guidance on the use of resources among comparisons</p> <p>Overall mean costs per patient have been shown to be lower among patients receiving PRA compared to HR by a mean difference of €–8126 (–14,660 to –1592), with an incremental cost-effectiveness of €–39,094 (95% bias-corrected and accelerated confidence interval –1213 to –116).²</p> <p>Among patients receiving LPL compared to HR, the difference in mean cost per patient was found to be lower by €–8,983 (95% confidence interval –16,232 to –1735) at 12 months and by €–19,794 (95% confidence interval –34,657 to –4,931) through a patient’s lifetime.³</p> <p>No cost data was found comparing PRA to LPL. Total costs were found to be lower with LPL compared to sigmoid resection (encompassing HR & PRA) with a mean difference of €–3,512, 95% bias-corrected and accelerated confidence interval –16,020 to 8,149. Stoma reversal increased costs in the sigmoid resection group, while surgical reintervention increased costs in the LPL group.⁴</p> <p>Summary</p> <p>The panel surmised that no important differences in resource utilization would be observed with PRA and that there is some evidence that it may result in lower costs compared to the alternatives of HR & LPL</p>	No important issues with the recommended alternative
Equity	<p>Research evidence</p> <p>No evidence on equity was identified</p> <p>Additional considerations</p> <p>The panel suggested that there is likely minimal variation in the effectiveness and access to care of the alternatives on population subgroups</p> <p>Summary</p> <p>The panel did not identify issues with equity among the alternatives</p>	No important issues with the recommended alternative

Table 1 (continued)

Acceptability	<p>Research evidence No evidence on acceptability was identified</p> <p>Additional considerations The panel agreed that both LPL and PRA were likely acceptable alternatives to HR. Current practice and cultural resistance to change likely do not pose barriers in this setting</p> <p>Summary The panel concluded that no variation in acceptability is anticipated</p>	No important issues with the recommended alternative
Feasibility	<p>Research evidence No evidence on feasibility was identified</p> <p>Additional considerations The panel suggested that there is likely minimal variation in the ability to perform the alternatives, though acknowledge that this may differ between institutions</p> <p>Summary No issues with feasibility were identified</p>	No important issues with the recommended alternative

*HR Hartmann's resection, LPL Laparoscopic peritoneal lavage, PRA Primary resection & anastomosis

surgeon's experience, expertise, and skills may call for joint decision-making.

Discussion

Implications for policy makers

Our international, multidisciplinary panel recommends PRA over HR or LPL among patients with complicated diverticulitis without sepsis. Policymakers must provide the infrastructure and incentive to facilitate this intervention. This may include justified financial billing codes in countries where this is applicable, as well as funding to cover surgeons and surgical trainees attending training courses or embarking on visiting fellowships in minimally invasive surgery and/or colorectal surgery. Healthcare institutions may consider offering around-the-clock colorectal service in regions with high prevalence of diverticulitis.

Implications for healthcare professionals

Surgeons and surgical trainees must be alert to the relative benefits of PRA over HR or LPL in the treatment of patients with complicated diverticulitis without sepsis. These clinicians are encouraged to secure additional training in the absence of the skills necessary to perform this intervention or ensure that patient access to PRA is

available through other means at their respective institutions. Surgeons and anesthesiologists must work collaboratively to decide on the use of HR versus PRA when identifying patients with sepsis or among immunocompromised patients.

Implications for patients

Collaborative, patient-centered decision-making is encouraged across all settings, as the importance placed on the quality of life with or without a stoma versus the risks and benefits of these interventions in the context of their values may differ among patients. Absolute risks of having a stoma at 1 year after index surgery and other decision aids are available on MAGICapp [<https://app.magicapp.org/#/guideline/7490>]. Surgeons may use these decision aids when discussing the comparative risks of different interventions with patients to help convey the frequency at which these risks occur. Specifically, for any given comparison of interventions, the decision aids display the numbers needed to treat in diaphramatic format for a given outcome. These are available in Supplementary Files 4, 5, and 6.

Moreover, patients may access the patient version of this guideline in Supplementary File 2. Patients may look toward the summary of the key points of the guideline to help them prepare with upcoming appointments with their gastrointestinal surgeon. The section “questions to ask your surgeon” is meant to probe and trigger patients to think more deeply about their health, values, and goals prior to discussing

surgical management of their complicated diverticulitis with their surgeon.

Implications for researchers

The following evidence gaps have been identified:

- Comparative evidence on the risks, benefits, and cost-effectiveness in frail patients receiving PRA, HR, and LPL for complicated diverticulitis—multicenter-matched cohort studies.
- Comparative evidence on the risks, benefits, and cost-effectiveness in immunocompromised patients receiving PRA, HR, and LPL for complicated diverticulitis—multicenter-matched cohort studies.
- Patient values and preferences in the quality of life with a stoma in the setting of acute as well as elective surgical repair of complicated diverticulitis—patient surveys and focus groups.

Barriers and facilitators

Resistance to change may be mitigated by embracing a culture of evidence-informed practice, starting with a top-down approach from leaders in surgical divisions across institutions. Availability of surgeons with sufficient skills and expertise in colorectal surgery to perform PRA can be improved by the increased availability and financial accessibility of training courses and visiting fellowships in both minimally invasive surgery and the technique of PRA for surgeons and surgical trainees, facilitated by financial support by policy makers. Patient-centered decision aids such as the one included in this guideline may help enable patients to engage in decisions about their treatment.

Monitoring

Use of the guideline will be monitored through engagement with EAES members through an online questionnaire within three years of publication. Additionally, use of the guideline will be monitored through the online traffic recorded by the journal of publication. Feedback from target users in the form of email communication, publications, and engagement on social media will be documented to inform future iterations of this guideline. We advise to monitor the implementation of this intervention at all respective institutions and to establish clinical outcomes among surgeons at all institutions for the purpose of quality improvement.

Validity period

Given that seven trials have been conducted in this field in the last few decades, we do not anticipate that new trials will substantially impact the evidence available for the comparison of PRA to HR and LPL over the next 7 years. This document is valid until December 2031.

Update

This guideline is planned to be updated within 2031, unless substantial new evidence will be published earlier.

Conclusion

Evidence-informed recommendations by an international, multidisciplinary panel of key stakeholders developed by EAES in collaboration with ESCP will guide treatment decisions among patients with complicated diverticulitis across Europe.

Supplementary Information The online version contains supplementary material available at <https://doi.org/10.1007/s00464-024-11445-y>.

Funding This project was funded by the European Association for Endoscopic Surgery & the European Society of Coloproctology. The funding bodies had no influence on the development of this rapid guideline or its protocol. There is no grant number linked to this research.

Declarations

Disclaimers This clinical practice guideline has been developed under the auspice of the European Association for Endoscopic Surgery (EAES). It is intended to be used primarily by health professionals (e.g., surgeons, anesthetists, physicians) and to assist in making informed clinical decisions on diagnostic measures and therapeutic management. It is also intended to inform individual practice of allied health professionals (e.g., surgical nurses, dieticians, physical rehabilitation therapists, psychologists); to inform strategic planning and resource management by health care authorities (e.g., regional and national authorities, health care institutions, hospital administration authorities); and to inform patients wishing to obtain an overview of the condition of interest and its management. The use of recommendations contained herein must be informed by supporting evidence accompanying each recommendation and by research evidence that might not have been published by the time of writing the present document. Users must thus base their actions informed by newly published evidence at any given point in time. The information in the guideline should not be relied upon as being complete or accurate, nor should it be considered as inclusive of all proper treatments or methods of care or as a statement of the standard of care. With the rapid development of scientific knowledge, new evidence may emerge between the time the guideline is developed and when it is published or read. The guideline is not continually updated and may not reflect the most recent evidence. The guideline addresses only the topics specifically identified therein and is not applicable to other interventions, diseases, or stages of diseases. This guideline does not mandate any particular course

of medical care. Further, the guideline is not intended to substitute the independent professional judgment of the treating provider, as the guideline does not necessarily account for individual variation among patients. Even if evidence on a topic suggests a specific diagnostic and/or treatment action, users and especially health professionals may need to decide against the suggested or recommended action in view of circumstances related to patient values, preferences, co-morbidities and disease characteristics; available human, financial and material resources; and healthcare infrastructures. EAES provides this guideline on an “as is” basis, and makes no warranty, express or implied, regarding the guideline.

Disclosures Stavros A. Antoniou, Bright Huo, Monica Ortenzi, Roi Anteby, Yegor Tryliskyy, Francesco Maria Carrano, Georgios Seitidis, Dimitris Mavridis, Vincent T. Hoek, Alberto Serventi, Willem A. Bemelman, Gian Andrea Binda, Rafael Duran, Triantafyllos Doulias, Nauzer Forbes, Nader K. Francis, Fabian Grass, Jesper Jensen, Marianne Krogsgaard, Lisa H. Massey, Luca Morelli, Christian E. Oberkoefler, Dorin E. Popa, Johannes Kurt Schultz, Shahnaz Sultan, Jean-Jacques Tuech, and Hendrik Jaap Bonjer declare no direct conflicts of interest related to this work. Indirect conflicts of external advisors were documented and managed as per Guidelines International Network Standards. Detailed conflict of interest statements of all contributors can be found in the online appendix [15]. A patient version of this guideline is available in Supplementary File 2.

Ethics approval Not applicable.

Consent to participate Not applicable.

References

- Delvaux M (2003) Diverticular disease of the colon in Europe: Epidemiology, impact on citizen health and prevention. *Aliment Pharmacol Ther* 18:71–74
- Acuna SA, Wood T, Chesney TR, Dossa F, Wexner SD, Quereshey FA, Chadi SA, Baxter NN (2018) Operative strategies for perforated diverticulitis: A Systematic Review and Meta-analysis. *Dis Colon Rectum* 61:1442–1453
- Francis NK, Sylla P, Abou-Khalil M, Arolfo S, Berler D, Curtis NJ, Dolejs SC, Garfinkle R, Gorter-Stam M, Hashimoto DA, Hassinger TE, Molenaar CJL, Pucher PH, Schuermans V, Arezzo A, Agresta F, Antoniou SA, Arulampalam T, Boutros M, Bouvy N, Campbell K, Francione T, Haggerty SP, Hedrick TL, Stefanidis D, Truitt MS, Kelly J, Ket H, Dunkin BJ, Pietrabissa A (2019) EAES and SAGES 2018 consensus conference on acute diverticulitis management: evidence-based recommendations for clinical practice. *Surg Endosc* 33:2726–2741
- Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (2019) Meta-regression. Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration and John Wiley & Sons Ltd, USA, pp 267–269
- Mbuagbaw L, Rochwerf B, Jaeschke R, Heels-Andsell D, Alhazani W, Thabane L, Guyatt GH (2017) Approaches to interpreting and choosing the best treatments in network meta-analyses. *Syst Rev* 6:79
- Hall J, Hardiman K, Lee S, Lightner A, Stocchi L, Paquette IM, Steele SR, Feingold DL (2020) The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Treatment of Left-Sided Colonic Diverticulitis. *Dis Colon Rectum* 63:728–747
- Schultz JK, Azhar N, Binda GA, Barbara G, Biondo S, Boermeester MA, Chabok A, Consten ECJ, van Dijk ST, Johansson A, Kruis W, Lambrichts D, Post S, Ris F, Rockall TA, Samuelsson A, Di Saverio S, Tartaglia D, Thorisson A, Winter DC, Bemelman W, Angenete E (2020) European Society of Coloproctology: guidelines for the management of diverticular disease of the colon. *Colorectal Dis* 22:5–28
- Sartelli M, Weber DG, Kluger Y, Ansaloni L, Coccolini F, Abu-Zidan F, Augustin G, Ben-Ishay O, Biffl WL, Bouliaris K, Catena R, Ceresoli M, Chiara O, Chiarugi M, Coimbra R, Cortese F, Cui Y, Damaskos D, De’ Angelis GL, Delibegovic S, Demetrashvili Z, De Simone B, Di Marzo F, Di Saverio S, Duane TM, Faro MP, Fraga GP, Gkiokas G, Gomes CA, Hardcastle TC, Hecker A, Karamarkovic A, Kashuk J, Khokha V, Kirkpatrick AW, Kok KYY, Inaba K, Isik A, Labricciosa FM, Latifi R, Leppäniemi A, Litvin A, Mazuski JE, Maier R V., Marwah S, McFarlane M, Moore EE, Moore FA, Negoi I, Pagani L, Rasa K, Rubio-Perez I, Sakakushev B, Sato N, Sganga G, Siquini W, Tarasconi A, Tolonen M, Ulrych J, Zachariah SK, Catena F, (2020) 2020 update of the WSES guidelines for the management of acute colonic diverticulitis in the emergency setting. *World J Emerg Surg* 15:32
- Schünemann H, Brożek J, Guyatt G, Oxman A (2013) GRADE Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach. Available at: <https://gdt.gradepro.org/app/handbook/handbook.html>. October 2013; Accessed 1 August 2024.
- Antoniou SA, Florez ID, Markar S, Logullo P, López-Cano M, Silecchia G, Antoniou GA, Tsokani S, Mavridis D, Brouwers M, Dayem YSA, Bertolaccini L, Alonso-Coello P, Akl E, Chand M, Como JJ, de Borst GJ, Di Saverio S, Emile S, Eom BW, Gorter R, Hanna G, Immonen K, Lai Q, Lumen N, Mathew JL, Montendori A, Moya M, Pellino G, Sanabria A, Saratzis A, Smart N, Stefanidis D, Zaninotto G (2022) AGREE-S: AGREE II extension for surgical interventions: appraisal instrument. *Surg Endosc* 36:5547–5558
- Institute of Medicine (U.S.). Committee on Standards for Developing Trustworthy Clinical Practice Guidelines., Graham R (2011) Clinical practice guidelines we can trust. National Academies Press, Washington DC, pp 1–266.
- Qaseem A, Forland F, Macbeth F, Phillips S, Van Der Wees P (2012) Guidelines international network: toward international standards for clinical practice guidelines. *Ann Intern Med* 3:525–531
- Garrity C, Gartlehner G, Nussbaumer-Streit B, King VJ, Hamel C, Kamel C, Affengruber L, Stevens A (2021) Cochrane Rapid Reviews Methods Group offers evidence-informed guidance to conduct rapid reviews. *J Clin Epidemiol* 130:13–22
- Schünemann HJ, Nieuwlaar R (2024) The INGUIDE international guideline training and certification programme. *Clin Publ Heal Guid* 1:1
- Antoniou S (2024) Online appendix of EAES Rapid Guideline: Management of complicated diverticulitis – with ESCP participation. Available at: https://osf.io/k4sh8/?view_only=b7e9c926976640d288878d1a7c2ee38f. March 2023; Accessed 1 August 2024.
- Huo B, Ortenzi M, Anteby R, Tryliskyy Y, Carrano FM, Seitidis G, Mavridis D, Hoek VT, Serventi A, Bemelman WA, Binda GA, Duran R, Doulias T, Forbes N, Francis NK, Grass F, Jensen J-et al (2024) Surgical management of complicated diverticulitis: systematic review and individual patient data network meta-analysis An EAES/ESCP collaborative project. *Surg. Endosc.*
- Schünemann HJ, AlAnsary LA, Forland F, Kersten S, Komulainen J, Kopp IB, Macbeth F, Phillips SM, Robbins C, Van Der Wees P, Qaseem A (2015) Guidelines international network: principles for disclosure of interests and management of conflicts in guidelines. *Ann Intern Med* 163:548–553

18. Ej H, Pg S, Gk R (1978) Treatment of perforated diverticular disease of the colon. *Adv Surg* 12:85–109
19. Guyatt GH, Oxman AD, Kunz R, Atkins D, Brozek J, Vist G, Alderson P, Glasziou P, Falck-Ytter Y, Schünemann HJ (2011) GRADE guidelines: 2. Framing the question and deciding on important outcomes. *J Clin Epidemiol* 64:395–400
20. Morgano GP, Mbuagbaw L, Santesso N, Xie F, Brozek JL, Siebert U, Bognanni A, Wiercioch W, Piggott T, Darzi AJ, Akl EA, Verstijnen IM, Parmelli E, Saz-Parkinson Z, Alonso-Coello P, Schünemann HJ (2022) Defining decision thresholds for judgments on health benefits and harms using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) Evidence to Decision (EtD) frameworks: a protocol for a randomised methodological study (GRADE-THRESHOLD). *BMJ Open* 12:e053246
21. Zeng L, Brignardello-Petersen R, Hultcrantz M, Siemieniuk RAC, Santesso N, Traversy G, Izcovich A, Sadeghirad B, Alexander PE, Devji T, Rochwerf B, Murad MH, Morgan R, Christensen R, Schünemann HJ, Guyatt GH (2021) GRADE guidelines 32: GRADE offers guidance on choosing targets of GRADE certainty of evidence ratings. *J Clin Epidemiol* 137:163–175
22. Guyatt G, Agoritsas T, Lytvyn L, Siemieniuk R, Vandvik P (2019) BMJ rapid recommendations: a possible revolution in clinical practice Guidelines. *CJGIM* 14:6–12
23. Nikolakopoulou A, Higgins JPT, Papakonstantinou T, Chaimani A, Del GC, Egger M, Salanti G (2020) Cinema: an approach for assessing confidence in the results of a network meta-analysis. *PLoS Med* 17:e1003082
24. Alonso-Coello P, Schünemann HJ, Moberg J, Brignardello-Petersen R, Akl EA, Davoli M, Treweek S, Mustafa RA, Rada G, Rosenbaum S, Morelli A, Guyatt GH, Oxman AD, Alonso P, Flottorp S, Gartlehner G, Glenton C, Meerpohl J, Parmelli E, Staney R, Vandvik P, Verstijnen I, Von Elm Bjorn E (2016) GRADE Evidence to Decision (EtD) frameworks: A systematic and transparent approach to making well informed healthcare choices. 1: Introduction. *BMJ* 353:i2016.
25. Hultcrantz M, Rind D, Akl EA, Treweek S, Mustafa RA, Iorio A, Alper BS, Meerpohl JJ, Murad MH, Ansari MT, Katikireddi SV, Östlund P, Tranæus S, Christensen R, Gartlehner G, Brozek J, Izcovich A, Schünemann H, Guyatt G (2017) The GRADE working group clarifies the construct of certainty of evidence. *J Clin Epidemiol* 87:4–13
26. Edomskis PP, Hoek VT, Stark PW, Lambrichts DPV, Draaisma WA, Consten ECJ, Bemelman WA, Lange JF (2022) Hartmann's procedure versus sigmoidectomy with primary anastomosis for perforated diverticulitis with purulent or fecal peritonitis: Three-year follow-up of a randomised controlled trial. *Int J Surg* 98:1–7
27. Azhar N, Johanssen A, Sundström T, Folkesson J, Wallon C, Kørner H, Blecic L, Forsmo HM, Øresland T, Yaqub S, Buchwald P, Schultz JK (2021) Laparoscopic lavage vs primary resection for acute perforated diverticulitis: long-term outcomes from the Scandinavian Diverticulitis (SCANDIV) randomized clinical trial. *JAMA Surg* 156:121–127
28. Loire M, Bridoux V, Mege D, MATHONNET M, Mauvais F, Massonnaud C, Regimbeau JM, Tuech JJ (2021) Long-term outcomes of Hartmann's procedure versus primary anastomosis for generalized peritonitis due to perforated diverticulitis: follow-up of a prospective multicenter randomized trial (DIVERTI). *Int J Colorectal Dis* 36:2159–2164
29. Lambrichts DPV, Vennix S, Musters GD, Mulder IM, Swank HA, Hoofwijk AGM, Belgers EHI, Stockmann HBAC, Eijssbouts QAJ, Gerhards MF, van Wagenveld BA, van Geloven AAW, Crolla RMPH, Nienhuijs SW, Govaert MJPM, di Saverio S, D'Hoore AJL, Consten ECJ, van Grevenstein WMU, Pierik REGJM, Kruij PM, van der Hoeven JAB, Steup WH, Catena F, Konsten JLM, Vermeulen J, van Dieren S, Bemelman WA, Lange JF, Hop WC, Opmeer BC, Reitsma JB, Scholte RA, Waltmann EWH, Legemate DA, Barteldsman JF, Meijer DW, Ünlü KAB, El-Massoudi Y, Vuylsteke R, Tanis PJ, Matthijsen R, Polle SW, Lagarde SM, Gisbertz SS, Wijers O, van der Bilt JDW, Boermeester MA, Blom R, Gooszen JAH, Schreinemacher MHF, van der Zande T, Leeuwenburgh MMN, Bartels SAL, Hesp WLEM, Koet L, van der Schelling GP, van Dessel E, van Zeeland MLP, Lensvelt MMA, Nijhof H, Verest S, Buijs M, Wijsman JH, Stassen LPS, Klinkert M, de Maat MFG, Sellenraad G, Jeekel J, Kleinrensink GJ, Thain T, Nijboer WN, Boom MJ, Verbeek PCM, Sietses C, Stommel MWJ, van Huijstee PJ, Merkus JWS, Eefting D, Mieog JSD, van Geldere D, Patijn GA, de Vries M, Boskamp M, Bentohami A, Bijlsma TS, de Korte N, Nio D, Rijna H, Luttikhoud J, van Gool MH, Fekkes JF, Akkersdijk GJM, Heuff G, Jutte EH, Kortmann BA, Werkman JM, Laméris W, Rietbergen L, Frankennmolen P, Draaisma WA, Stam MAW, Verweij MS, Karsten TM, de Nes LC, Fortuin S, de Castro SM, Doeksen A, Simons MP, Koffeman GI, Steller EP, Tuynman JB, Boele van Hensbroek P, Mok M, van Diepen SR, Hulsewé KWE, Melenhorst J, Stoot JHMB, Fransen S, Sosef MN, van Bastelaar J, Vissers YLJ, Douchy TPD, Christiaansen CE, Smeenk R, Pijnenburg AM, Tanaydin V, Veger HTC, Clermonts SHEMA, Al-Taher M, de Graaf EJR, Menon AG, Vermaas M, Cense HA, Jutte E, Wiezer MJ, Smits AB, Westerterp M, Marsman HA, Hendriks ER, van Ruler O, Vriens EJC, Vogten JM, van Rossem CC, Ohanis D, Tanis E, van Grinsven J, Maring JK, Heisterkamp J, Besselink MGH, Borel Rinkes IHM, Moleenaar IQ, Joosten JJA, Jongkind V, Diepenhorst GMP, Boule MC, Smeenge M, Nielsen K, Harlaar JJ, Luyer MDP, van Montfort G, Smulders JF, Daams F, van Haren E, Nieuwenhuijzen GAP, Lauret GJ, Pereboom ITA, Stokmans RA, Birindelli A, Bianchi E, Pellegrini S, Terrasson I, Wolthuis A, de Buck van Overstraeten A, Nijs S, (2019) Hartmann's procedure versus sigmoidectomy with primary anastomosis for perforated diverticulitis with purulent or faecal peritonitis (LADIES): a multicentre, parallel-group, randomised, open-label, superiority trial. *Lancet Gastroenterol Hepatol* 4:599–610
30. Kohl A, Rosenberg J, Bock D, Bisgaard T, Skullman S, Thornell A, Gehrman J, Angenete E, Haglind E (2018) Two-year results of the randomized clinical trial DILALA comparing laparoscopic lavage with resection as treatment for perforated diverticulitis. *Br J Surg* 105:1128–1134
31. Bridoux V, Regimbeau JM, Ouassini M, MATHONNET M, Mauvais F, Houivet E, Schwarz L, Mege D, Sielezneff I, Sabbagh C, Tuech JJ (2017) Hartmann's procedure or primary anastomosis for generalized peritonitis due to perforated diverticulitis: a prospective multicenter randomized trial (DIVERTI). *J Am Coll Surg* 225:798–805
32. Schultz JK, Wallon C, Blecic L, Forsmo HM, Folkesson J, Buchwald P, Kørner H, Dahl FA, Øresland T, Yaqub S, Papp A, Ersson U, Zittel T, Fagerström N, Gustafsson D, Dafnis G, Cornelius M, Egenvall M, Nyström PO, Syk I, Vilhjalmsdottir D, Arbmán G, Chabok A, Helgeland M, Bondi J, Husby A, Helander R, Kjos A, Gregussen H, Talabani AJ, Tranø G, Nygaard IH, Wiedswang G, Sjø OH, Desserud KF, Norderval S, Gran MV, Pettersen T, Sæther A (2017) One-year results of the SCANDIV randomized clinical trial of laparoscopic lavage versus primary resection for acute perforated diverticulitis. *Br J Surg* 104:1382–1392
33. Angenete E, Thornell A, Burcharth J, Pommergaard HC, Skullman S, Bisgaard T, Jess P, Läckberg Z, Matthiessen P, Heath J, Rosenberg J, Haglind E (2016) Laparoscopic lavage is feasible and safe for the treatment of perforated diverticulitis with purulent peritonitis: The first results from the randomized controlled trial DILALA. *Ann Surg* 263:117–122
34. Vennix S, Musters GD, Mulder IM, Swank HA, Consten EC, Belgers EH, van Geloven AA, Gerhards MF, Govaert MJ, van Grevenstein WM, Hoofwijk AG, Kruij PM, Nienhuijs SW,

- Boermeester MA, Vermeulen J, van Dieren S, Lange JF, Bemelman WA, Hop WC, Opmeer BC, Reitsma JB, Scholte RA, Waltmann EWH, Legemate DA, Bartelsman JF, Meijer DW, de Brouwer M, van Dalen J, Durbridge M, Geerdink M, Ilbrink GJ, Mehmedovic S, Middelhoek P, Boom MJ, Consten ECJ, van der Bilt JDW, van Olden GDJ, Stam MAW, Verweij MS, Busch ORC, Buskens CJ, El-Massoudi Y, Kluit AB, van Rossem CC, Schijven MP, Tanis PJ, Unlu C, Karsten TM, de Nes LC, Rijna H, van Wagenveld BA, Koffeman GI, Steller EP, Tuynman JB, Bruin SC, van der Peet DL, Blanken-Peters CFJM, Cense HA, Jutte E, Crolla RMPH, van der Schelling GP, van Zeeland M, de Graaf EJ, Groenendijk RPR, Karsten TM, Vermaas M, Schouten O, de Vries MR, Prins HA, Lips DJ, Bosker RJI, van der Hoeven JAB, Diks J, Plaisier PW, Sietses C, Stommel MWJ, de Hingh IHJT, Luyer MDP, van Montfort G, Ponten EH, Smulders JF, van Duyn EB, Klaase JM, Swank DJ, Ottow RT, Stockmann HBAC, Vermeulen J, Vuylsteke RJCLM, Belgers HJ, Fransen S, von Meijenfildt EM, Sosef MN, van Geloven AAW, Hendriks ER, ter Horst B, Leeuwenburgh MMN, van Ruler O, Vogten JM, Vriens EJC, Westerterp M, Eijssbouts QAJ, Bentohami A, Bijlsma TS, de Korte N, Nio D, Govaert MJPM, Joosten JJA, Tollenaar RAEM, Stassen LPS, Wiezer MJ, Hazebroek EJ, Smits AB, van Westreenen HL, Brandt A, Nijboer WN, Toorenvliet BR, Weidema WF, Coene PPLO, Mannaerts GHH, den Hartog D, de Vos RJ, Zengerink JF, Hoofwijk AGM, Hulsewé KWE, Melenhorst J, Stoot JHMB, Steup WH, Huijstee PJ, Merkus JWS, Wever JJ, Maring JK, Heisterkamp J, van Grevenstein WMU, Vriens MR, Besselink MGH, Borel Rinkes IHM, Witkamp AJ, Slooter GD, Konsten JLM, Engel AF, Pierik EGJM, Frakking TG, van Geldere D, Patijn GA, D'Hoore AJL, de Buck van Overstraeten A, Miserez M, Terrasson I, Wolthuis A, Di Saverio S, de Blasiis MG, (2015) Laparoscopic peritoneal lavage or sigmoidectomy for perforated diverticulitis with purulent peritonitis: A multicentre, parallel-group, randomised, open-label trial. *Lancet* 386:1269–1277
35. Schultz JK, Yaqub S, Wallon C, Blecic L, Forsmo HM, Folkesson J, Buchwald P, Körner H, Dahl FA, Øresland T, Papp A, Ersson U, Zittel T, Fagerström N, Gustafsson D, Dafnis G, Cornelius M, Egenvall M, Nyström PO, Syk I, Vilhjalmsson D, Pahlman L, Arbmán G, Chabok A, Helgeland M, Bondi J, Husby A, Helander R, Kjos A, Gregussen H, Talabani AJ, Tranø G, Nygaard IH, Wiedswang G, Sjø OH, Desserud KF, Norderval S, Gran MV, Pettersen T, Sæther A (2015) Laparoscopic lavage vs primary resection for acute perforated diverticulitis: The SCANDIV randomized clinical trial. *JAMA* 314:1364–1375
 36. Binda GA, Karas JR, Serventi A, Sokmen S, Amato A, Hydo L, Bergamaschi R (2012) Primary anastomosis vs nonrestorative resection for perforated diverticulitis with peritonitis: A prematurely terminated randomized controlled trial. *Colorectal Dis* 14:1403–1410
 37. Oberkofler CE, Rickenbacher A, Raptis DA, Lehmann K, Villiger P, Buchli C, Grieder F, Gelpke H, Decurtins M, Tempia-Caliera AA, Demartines N, Hahnloser D, Clavien P-A, Breitenstein S (2012) A multicenter randomized clinical trial of primary anastomosis or Hartmann's procedure for perforated left colonic diverticulitis with purulent or fecal peritonitis. *Ann Surg* 256:819–827
 38. Hoek VT, Edomskis PP, Stark PW, Lambrechts DPV, Draaisma WA, Consten ECJ, Lange JF, Bemelman WA, Hop WC, Opmeer BC, Reitsma JB, Scholte RA, Waltmann EWH, Legemate A, Bartelsman JF, Meijer DW, de Brouwer M, van Dalen J, Durbridge M, Geerdink M, Ilbrink GJ, Mehmedovic S, Middelhoek P, Boom MJ, Consten ECJ, van der Bilt JDW, van Olden GDJ, Stam MAW, Verweij MS, Vennix S, Musters GD, Swank HA, Boermeester MA, Busch ORC, Buskens CJ, El-Massoudi Y, Kluit AB, van Rossem CC, Schijven MP, Tanis PJ, Unlu C, van Dieren S, Gerhards MF, Karsten TM, de Nes LC, Rijna H, van Wagenveld BA, Koffeman GI, Steller EP, Tuynman JB, Bruin SC, van der Peet DL, Blanken-Peters CFJM, Cense HA, Jutte E, Crolla RMPH, van der Schelling GP, van Zeeland M, de Graaf EJ, Groenendijk RPR, Karsten TM, Vermaas M, Schouten O, de Vries MR, Prins HA, Lips DJ, Bosker RJI, van der Hoeven JAB, Diks J, Plaisier PW, Kruyt PM, Sietses C, Stommel MWJ, Nienhuijs SW, de Hingh IHJT, Luyer MDP, van Montfort G, Ponten EH, Smulders JF, van Duyn EB, Klaase JM, Swank DJ, Ottow RT, Stockmann HBAC, Vermeulen J, Vuylsteke RJCLM, Belgers HJ, Fransen S, von Meijenfildt EM, Sosef MN, van Geloven AAW, Hendriks ER, ter Horst B, Leeuwenburgh MMN, van Ruler O, Vogten JM, Vriens EJC, Westerterp M, Eijssbouts QAJ, Bentohami A, Bijlsma TS, de Korte N, Nio D, Govaert MJPM, Joosten JJA, Tollenaar RAEM, Stassen LPS, Wiezer MJ, Hazebroek EJ, Smits AB, van Westreenen HL, Lange JF, Brandt A, Nijboer WN, Mulder IM, Toorenvliet BR, Weidema WF, Coene PPLO, Mannaerts GHH, den Hartog D, de Vos RJ, Zengerink JF, Hoofwijk AGM, Hulsewé KWE, Melenhorst J, Stoot JHMB, Steup WH, Huijstee PJ, Merkus JWS, Wever JJ, Maring JK, Heisterkamp J, van Grevenstein WMU, Vriens MR, Besselink MGH, Borel Rinkes IHM, Witkamp AJ, Slooter GD, Konsten JLM, Engel AF, Pierik EGJM, Frakking TG, van Geldere D, Patijn GA, D'Hoore BAJL, de Buck A van O, Miserez M, Terrasson I, Wolthuis A, di Saverio S, de Blasiis MG, (2022) Laparoscopic peritoneal lavage versus sigmoidectomy for perforated diverticulitis with purulent peritonitis: three-year follow-up of the randomised LOLA trial. *Surg Endosc* 36:7764–7774
 39. Thornell A, Angenete E, Bisgaard T, Bock D, Burchard J, Heath J, Pommersgaard HC, Rosenberg J, Stilling N, Skullman S, Haglund E (2016) Laparoscopic lavage for perforated diverticulitis with purulent peritonitis. *Ann Intern Med* 164:137–145
 40. Shankar-Hari M, Phillips GS, Levy ML, Seymour CW, Liu VX, Deutschman CS, Angus DC, Rubenfeld GD, Singer M (2016) Developing a new definition and assessing new clinical criteria for septic shock: For the third international consensus definitions for sepsis and septic shock (sepsis-3). *JAMA* 315:775–787
 41. Dossa F, Josse J, Acuna SA, Baxter NN (2018) Health state utility values for ileostomies and colostomies: a systematic review and meta-analysis. *J Gastrointest Surg* 22(5):894–905. <https://doi.org/10.1007/s11605-018-3671-7>
 42. Lambrechts DPV, van Dieren S, Bemelman WA, Lange JF. (2020). Cost-effectiveness of sigmoid resection with primary anastomosis or end colostomy for perforated diverticulitis: an analysis of the randomized Ladies trial. *Br J Surg*. 107(12): 1686–1694. <https://doi.org/10.1002/bjs.11715>.
 43. Gehrman J, Angenete E, Bjørholt I, Bock D, Rosenberg J, Haglund E. (2016). Health economic analysis of laparoscopic lavage versus Hartmann's procedure for diverticulitis in the randomized DILALA trial. *Br J Surg*. 103(11):1539–47. <https://doi.org/10.1002/bjs.10230>.
 44. Vennix S, van Dieren S, Opmeer BC, Lange JF, Bemelman WA (2017) Cost analysis of laparoscopic lavage compared with sigmoid resection for perforated diverticulitis in the Ladies trial. *Br J Surg* 104(1):62–68. <https://doi.org/10.1002/bjs.10329>

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted

manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Authors and Affiliations

Stavros A. Antoniou^{1,2} · Bright Huo³  · Monica Ortenzi⁴ · Roi Anteby^{5,6} · Yegor Trylisky⁷ · Francesco Maria Carrano⁸ · Georgios Seitidis⁹ · Dimitris Mavridis⁹ · Vincent T. Hoek¹⁰ · Alberto Serventi¹¹ · Willem A. Bemelman¹² · Gian Andrea Binda¹³ · Rafael Duran¹⁴ · Triantafyllos Doulias^{15,16,17} · Nauzer Forbes^{18,19} · Nader K. Francis²⁰ · Fabian Grass²¹ · Jesper Jensen²² · Marianne Krosggaard²³ · Lisa H. Massey²⁴ · Luca Morelli²⁵ · Christian E. Oberkofler^{26,27} · Dorin E. Popa²⁸ · Johannes Kurt Schultz^{29,30,31} · Shahnaz Sultan³² · Jean-Jacques Tuech³³ · Hendrik Jaap Bonjer^{34,35}

✉ Stavros A. Antoniou
stavros.antoniou@hotmail.com; guidelines@eaes.eu

¹ Department of Surgery, Papageorgiou General Hospital, Thessaloniki, Greece

² Guidelines Committee, European Association for Endoscopic Surgery, Eindhoven, Netherlands

³ Division of General Surgery, Department of Surgery, McMaster University, Hamilton, ON, Canada

⁴ Department of General and Emergency Surgery, Polytechnic University of Marche, Ancona, Italy

⁵ Department of Surgery B, Sheba Medical Center, Tel Hashomer, Israel

⁶ Faculty of Medicine, Tel-Aviv University, Tel Aviv-Yafo, Israel

⁷ Great Western Hospitals, NHS, Swindon, UK

⁸ Department of Medical and Surgical Sciences and Translational Medicine, Faculty of Medicine and Psychology, St Andrea Hospital, Sapienza University, Rome, Italy

⁹ Department of Primary Education, School of Education, University of Ioannina, Ioannina, Greece

¹⁰ Department of Surgery, Erasmus University Medical Centre, Rotterdam, Netherlands

¹¹ Department of Surgery, Ospedale Mons Galliano, Acqui Terme (AL), Italy

¹² Department of Surgery, Amsterdam University Medical Centers, Amsterdam, Netherlands

¹³ General Surgery, Biomedical Institute, 16152 Genoa, Italy

¹⁴ Department of Radiology and Interventional Radiology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland

¹⁵ Department of Colorectal Surgery, Colchester Hospital, East Suffolk and North Essex NHS Foundation Trust, Colchester, UK

¹⁶ Colorectal Surgery Department, Kettering Hospital, University Hospitals of Northamptonshire, Kettering, Northamptonshire, UK

¹⁷ Department of Genetics and Genome Biology, Honorary Lecturer in the Leicester Cancer Research Centre, Leicester, UK

¹⁸ Department of Community Health Sciences, University of Calgary, Calgary, AB, Canada

¹⁹ Division of Gastroenterology and Hepatology, Department of Medicine, University of Calgary, Calgary, AB, Canada

²⁰ Northwick Park and St Mark's Hospital, The Griffin Institute, London, UK

²¹ Department of Visceral Surgery, Lausanne University Hospital CHUV, University of Lausanne (UNIL), Lausanne, Switzerland

²² Patient Partner, Roskilde, Denmark

²³ Department of Surgery, Zealand University Hospital, Koege, Denmark

²⁴ Department of Colorectal Surgery, Nottingham University Hospitals NHS Trust, Nottingham, UK

²⁵ Division of Translational and New Technologies in Medicine and Surgery, General Surgery Department, University of Pisa, Pisa, Italy

²⁶ Swiss HPB and Transplantation Center, Department of Surgery and Transplantation, University Hospital Zurich, Zurich, Switzerland

²⁷ Vivévis - Clinic Hirslanden Zurich, Zurich, Switzerland

²⁸ Department of Surgery, Linköping University Hospital, Linköping, Sweden

²⁹ Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway

³⁰ Department of Pediatric and Gastrointestinal Surgery, Oslo University Hospital, 0424 Oslo, Norway

³¹ Department of Gastrointestinal Surgery, Akershus University Hospital, Lørenskog, Norway

³² Department of Medicine, Division of Gastroenterology, University of Minnesota, Minneapolis, MN, USA

³³ Department of Digestive Surgery, Rouen University Hospital, 1 Rue de Germont, 76000 Rouen, France

³⁴ Cancer Center Amsterdam, Amsterdam, Netherlands

³⁵ Department of Surgery, Amsterdam UMC, Location Vrije Universiteit, Amsterdam, Netherlands